Zoledronate to prevent bone loss in acute multiple sclerosis
Completed
- Conditions
- Multiple sclerosisNervous System Diseases
- Registration Number
- ISRCTN87039596
- Lead Sponsor
- orth Bristol NHS Trust (UK)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
1. Aged 18 - 65 years (either sex) with a diagnosis of multiple sclerosis (MS)
2. Acute flare up requiring treatment with a corticosteroid
3. Able to attend for study investigations and assessments
4. Willing and able to provide informed consent
Exclusion Criteria
1. Previous diagnosis of osteoporosis
2. Bone therapy within previous 12 months
3. Previous bisphosphonate therapy at any time
4. Associated disorder that may affect bone metabolism
5. Pregnancy
6. Breastfeeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A significant difference in serum type I collagen C-telopeptides (CTX) according to treatment group at day 7 of the study
- Secondary Outcome Measures
Name Time Method Increased bone mineral density (BMD), measured at days 7, 90,180 and 360